
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
in Human Breast Carcinoma
Manitoba Institute of Cell Biology and Departments of 1 Pathology and 2 Biochemistry and Medical Genetics, University of Manitoba, Faculty of Medicine, Winnipeg, Manitoba, Canada; and 3 Department of Surgery, Cancer Hospital/Cancer Institute, Fudan University, Shanghai, China
Purpose: Hypoxia may influence gene expression to promote malignancy, and acute hypoxia has been shown to transiently repress estrogen receptor (ER)-
expression in breast cell lines. However, the effect of intermittent hypoxia, which is likely more prevalent in breast cancers, remains to be determined.
Experimental Design: ER-
expression was assessed by Western blot and immunohistochemistry in a selected cohort of 51 ER-
positive breast carcinomas, in relation to markers of hypoxia. The effect of acute and intermittent hypoxia on ER-
expression was also determined in MCF7 and ZR-75 breast cell lines, together with the role of proteasome function with the proteasome inhibitor bortezomib.
Results: Regional loss of ER-
expression occurs in breast tumors and is consistently present in hypoxic regions defined by the proximity of necrosis and induction of hypoxia-induced genes carbonic anhydrase IX (CA-IX) and glucose transporter 1 (Glut-1), in both in situ (n = 29; P < 0.0001) and invasive (n = 20; P = 0.0001) carcinomas. In MCF7 and ZR-75 cells, ER-
is transiently down-regulated by acute hypoxia and rapidly restored by reoxygenation. However, intermittent, acute hypoxia can cause a similar down-regulation of ER-
that is not attributable to decreased mRNA and persists in MCF7 cells despite reoxygenation for up to 14 days. This effect occurs with no change in cell viability but a corresponding reduction in growth response to estradiol. However, ER-
expression can be restored by bortezomib.
Conclusions: Intermittent hypoxia can cause persistent changes in proteasome function that may contribute to reduced ER-
expression in breast tumors and consequently to diminished response and development of resistance to endocrine therapy.
This article has been cited by other articles:
![]() |
J. Q. Brown, L. G. Wilke, J. Geradts, S. A. Kennedy, G. M. Palmer, and N. Ramanujam Quantitative Optical Spectroscopy: A Robust Tool for Direct Measurement of Breast Cancer Vascular Oxygenation and Total Hemoglobin Content In vivo Cancer Res., April 1, 2009; 69(7): 2919 - 2926. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Generali, S. B Fox, A. Berruti, M. P Brizzi, L. Campo, S. Bonardi, S. M Wigfield, P. Bruzzi, A. Bersiga, G. Allevi, et al. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 921 - 930. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |